Inhibition of Anthrax Lethal Toxin-Induced Cytolysis of RAW264.7 Cells by Celastrol by Chapelsky, Sarah et al.
Inhibition of Anthrax Lethal Toxin-Induced Cytolysis of
RAW264.7 Cells by Celastrol
Sarah Chapelsky, Sarah Batty, Mia Frost, Jeremy Mogridge*
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Background. Bacillus anthracis is the bacterium responsible for causing anthrax. The ability of B. anthracis to cause disease is
dependent on a secreted virulence factor, lethal toxin, that promotes survival of the bacteria in the host by impairing the
immune response. A well-studied effect of lethal toxin is the killing of macrophages, although the molecular mechanisms
involved have not been fully characterized. Methodology/Principal Findings. Here, we demonstrate that celastrol, a quinone
methide triterpene derived from a plant extract used in herbal medicine, inhibits lethal toxin-induced death of RAW264.7
murine macrophages. Celastrol did not prevent cleavage of mitogen activated protein kinase kinase 1, a cytosolic target of the
toxin, indicating that it did not inhibit the uptake or catalytic activity of lethal toxin. Surprisingly, celastrol conferred almost
complete protection when it was added up to 1.5 h after intoxication, indicating that it could rescue cells in the late stages of
intoxication. Since the activity of the proteasome has been implicated in intoxication using other pharmacological agents, we
tested whether celastrol blocked proteasome activity. We found that celastrol inhibited the proteasome-dependent
degradation of proteins in RAW264.7 cells, but only slightly inhibited proteasome-mediated cleavage of fluorogenic substrates
in vitro. Furthermore, celastrol blocked stimulation of IL-18 processing, indicating that celastrol acted upstream of
inflammasome activation. Conclusions/Significance. This work identifies celastrol as an inhibitor of lethal toxin-mediated
macrophage lysis and suggests an inhibitory mechanism involving inhibition of the proteasome pathway.
Citation: Chapelsky S, Batty S, Frost M, Mogridge J (2008) Inhibition of Anthrax Lethal Toxin-Induced Cytolysis of RAW264.7 Cells by Celastrol. PLoS
ONE 3(1): e1421. doi:10.1371/journal.pone.0001421
INTRODUCTION
Anthrax lethal toxin (LeTx) comprises two proteins that are
secreted separately by Bacillus anthracis and that form complexes on
the surface of mammalian cells [1]. The protective antigen (PA)
component of the toxin binds host cellular receptors and is
proteolytically activated by furin-like proteases. The proteolytic
activation of PA causes dissociation of an amino-terminal fragment
of the protein, which allows the homo-oligomerization of the
receptor-bound carboxy-terminal fragment, PA63. Heptamers of
PA63 bind the second toxin component, lethal factor (LF) [2–4].
These toxin complexes are internalized by receptor-mediated
endocytosis and LF is delivered to the cytosol after translocating
through a membrane-spanning pore formed by the heptamer
[5,6]. LF disrupts signaling pathways by cleaving members of the
mitogen activated protein kinase kinase (MAPKK) family, thereby
interfering with normal cellular functions [7].
The contribution of LeTx to anthrax pathogenesis is complex
and is likely mediated through several different mechanisms and
cell types [8]. The relative importance to pathogenesis of each of
the effects of intoxication is unknown and may differ depending on
the site of infection and the infection model. Numerous reports
support the notion that the toxin disrupts the immune system,
which would aid bacterial survival and support disease progres-
sion. LeTx inhibits cytokine expression in T cells, dendritic cells,
macrophages, and endothelial cells [9–13]. LeTx inhibits produc-
tion of Type IIA phospholipase A2 by macrophages [14],
differentiation of monocytes into macrophages [15], production
of immunoglobulin by B cells [16], production of superoxide by
neutrophils [17], and impairs neutrophil motility [18]. In addition,
LeTx causes cytoxicity in macrophages, dendritic cells and certain
types of endothelial cells [19–21].
Macrophages seem to both promote and control anthrax
infections. Phagocytosis of B. anthracis spores by macrophages
promotes their germination [22]; but macrophages reduce
susceptibility of mice to anthrax infections [23], probably through
direct killing of extracellular bacilli. Intoxication of macrophages
influences both of these interactions: first, by facilitating the escape
of bacilli that have germinated from phagocytosed spores [24], and
second, by killing macrophages that can destroy the bacilli.
Macrophages derived from some strains of mice undergo
cytolysis after being exposed to LeTx and it was discovered
recently that susceptibility to LeTx-induced cytolysis is determined
by the allele of the Nalp1b gene [25]. Human NALP1 is a
component of the inflammasome, which is a complex consisting of
NALP1, ASC, caspase-1 and caspase-5 [26]. Assembly of the
inflammasome activates caspase-1 and caspase-5, leading to the
processing of pro-inflammatory cytokines IL-1b and IL-18.
Activation of caspase-1 by murine Nalp1b mediates macrophage
cytolysis through the mitochondrial proteins Bnip3 and Bnip3L
[25,27], but it is unclear why the inflammasome is activated by the
action of LeTx. LeTx-mediated cytolysis of the susceptible
macrophage cell line J774A.1 is accompanied by a proteasome-
dependent loss of mitochondrial membrane potential and
membrane swelling [28–30]. Subsequent to impairment of
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drop, and cytolysis occurs [29].
Celastrol is a small molecule derived from the plant Triptergium
wilfordii that has been shown to have cytoprotective properties
[31,32], so we sought to determine whether celastrol could protect
macrophages from LeTx-induced cytolysis. In this study, we
demonstrated that celastrol inhibited LeTx-mediated death of the
murine macrophage cell line RAW264.7. Celastrol did not inhibit
cleavage of MAPKK1, indicating that it did not block toxin
internalization or the proteolytic activity of LF. Furthermore,
celastrol was able to protect cells that had been pre-exposed to the
toxin, suggesting that it inhibited a late stage of intoxication. We
found that celastrol blocked proteasome-mediated destruction of
ubiquitylated proteins and prevented LeTx-stimulated processing
of IL-18, suggesting that the cytoprotective effects of celastrol are a
result of its ability to inhibit the proteasome pathway, thereby
preventing inflammasome activation.
MATERIALS AND METHODS
Reagents
Celastrol, rabbit 20S proteasome, and Z-Leu-Leu-Glu-7-amido-4-
methylcoumarin (Z-LLE-AMC) were obtained from Calbiochem.
MG132, lipopolysaccharide (cat. # L2630), 7-amino-4-methyl-
coumarine (AMC), and N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-
methylcoumarin (Suc-LLVY-AMC) were obtained from Sigma.
Glutathione-agarose immobilised GST-S5a, purified 26S protea-
some, ATP (cat. # EW9805), t-butoxycarbonyl-Leu-Arg-Arg-7-
amido-4-methylcoumarin (Boc-LRR-AMC), and acetyl-L-norleu-
cyl-L-prolyl-L-norleucyl-L-aspartyl-methylcoumarylamide (Ac-
nLPnLD-AMC) were obtained from Biomol International. PA
and LF were purified as described previously [15].
Cell culture and cytotoxicity assays
RAW 264.7 cells were maintained in RPMI supplemented with
5% fetal bovine serum and 1% penicillin-streptomycin. For
cytotoxicity assays, cells were seeded into tissue culture-treated
polystyrene 96-well plates (Corning) at a density of 10
5 viable cells
per well and incubated overnight at 37uC and 5% CO2. Cells
treated with LeTx were exposed to 10
28 M PA and 5610
210 M
LF. Cell viability was assessed using the CellTiter 96 Aqueous One
Solution Cell Proliferation assay (Promega), as per manufacturer’s
instructions.
Western blot assays
Cells were harvested in 16 Cell Lysis Buffer (Cell Signaling
Technologies) containing 1 mM phenylmethylsulfonyl fluoride
and were sonicated (3615 seconds). Lysates were cleared by
centrifugation; equal amounts of protein were separated on an
SDS-polyacrylamide gel and transferred to nitrocellulose. Mem-
branes were blocked in 0.1% Tween-20 TBS (100 mM Tris-HCl
pH 8.0, 0.9% NaCl) containing 5% skim milk powder, and were
probed with primary antibodies. Antibodies raised against IL-18
(BioVision), IkBa (Santa Cruz Technologies), ubiquitin (Dako), a-
tubulin (Sigma), and the N-terminus of MAPKK1 (Upstate
Technologies) were used according to manufacturer’s instructions.
GST-S5a agarose pulldown
Cell lysates were prepared from RAW264.7 cells that had been
treated with 10 mM MG132 for 1 h. GST or GST-S5a coupled to
sepharose (20 mL of 0.5 mg protein/mL resin) was combined with
50 mg lysate in 250 mL of Cell Lysis Buffer (Cell Signaling
Technologies) containing 5% glycerol. This mixture was rotated at
4uC for 2 h, either in the presence or absence of 10 mM celastrol.
Beads were washed three times with lysis buffer, and proteins were
eluted with SDS loading dye. Western blot analysis was performed
using anti-ubiquitin antibody.
20S proteasome proteolytic acitivity
Reactions were carried out in 50 mM Tris-HCl pH 8.0 containing
0.03% SDS in a volume of 200 mL. Suc-LLVY-AMC was used at
a final concentration of 30 mM, and 0.4 mg of 20S proteasome was
used per reaction. A constant concentration of 0.4% DMSO was
maintained in all wells. Fluorescence (excitation 380 nm, emission
460 nm) was measured every 30 s for 40 min. The slope of the
initial linear portion of the curve (over a 15 min interval) was
determined using Prism 3.0 (GraphPad Software Inc.). Standard
curves were generated using AMC in the presence of the
compounds tested, and the amount of AMC liberated per unit
time was calculated.
26S proteasome proteolytic activity
Reactions were carried out in 50 mM Tris-HCl pH 7.5 containing
40 mM KCl, 5 mM magnesium chloride, 0.5 mM ATP, 1 mM
DTT, and 0.5 mg/mL BSA in a volume of 200 mL. Suc-LLVY-
AMC, Ac-nLPnLD-AMC, and Boc-LRR-AMC were used at a
final concentration of 100 mM. To measure cleavage of Suc-
LLVY-AMC, 0.2 mg of 26S proteasome was used per reaction.
For the other substrates, 0.75 mg of 26S proteasome was used. A
constant concentration of 1% DMSO was maintained in all wells.
Fluorescence (excitation 380 nm, emission 460 nm) was measured
every 30 s for 2 h. The slope of the initial linear portion of the
curve (over a 15 min interval) was determined using Prism 3.0
(GraphPad Software Inc.). Standard curves were generated using
AMC in the presence of the compounds tested, and the amount of
AMC liberated per unit time was calculated.
Proteasome proteolytic acitivity of RAW264.7 cell
lysates
RAW264.7 cells were washed twice with PBS and suspended in
reaction buffer (50 mM Tris-HCl pH 7.5 containing 250 mM
sucrose, 5 mM magnesium chloride, 2 mM ATP, 1 mM DTT,
and 0.5 mM EDTA). Cells were sonicated for 15 s and lysates
were cleared by centrifugation. Reactions were performed in a
volume of 200 mL, using a final concentration of 100 mM Suc-
LLVY-AMC and 25 mg protein lysate per reaction. A constant
concentration of 1% DMSO was maintained in all wells.
Fluorescence was measured and data was analyzed as described
above for the 26S proteasome assay.
RESULTS AND DISCUSSION
To determine whether celastrol can protect RAW264.7 cells from
LeTx-induced death, we treated cells for 4 h with LeTx in the
absence or presence of celastrol. Cell viability was estimated using
the MTS assay, which measures the reduction of a tetrazolium salt
to formazan by metabolically active cells. Treatment of cells with
LeTx (10
28 M PA and 5610
210 M LF) alone reduced metabolic
activity, whereas treatment with 3 mM celastrol alone had little
effect (Fig. 1A). Cells that were co-treated with LeTx and celastrol
exhibited metabolic activity similar to untreated cells. Celastrol
also protected the J774A.1 murine macrophage cell line from
intoxication (data not shown), demonstrating that this activity is
not restricted to RAW264.7 cells.
We next sought to determine whether celastrol inhibited either
toxin internalization or the enzymatic activity of LF by monitoring
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with LeTx, celastrol, or both for 1 h. Cellular extracts were
prepared and examined by Western blotting using an antibody
that recognizes the amino terminus of MAPKK1; LF cleaves an
amino-terminal segment from MAPKK1, so this antibody does
not detect the cleaved protein. A reduced amount of full-length
MAPKK1 was observed in cells treated with LeTx compared to
untreated cells (Fig. 1B). Celastrol did not prevent cleavage of
MAPPK1 by LeTx, however, indicating that celastrol did not
inhibit the delivery of LF to the cytosol or the proteolytic activity of
this enzyme.
Since celastrol did not inhibit substrate cleavage by LF, this
result indicated that this compound might block a late step in
intoxication. To address this possibility, we performed a time-
course assay to determine how late during intoxication celastrol
could confer protection (Figs. 1C, D). Celastrol was added to cells
at different times after toxin addition and the MTS assay was
performed 4 h after the toxin was added. In parallel, cells were
treated for different amounts of time with LeTx alone to assess the
metabolic activity of cells at the times of celastrol addition. A slight
reduction in metabolic activity was observed after 1 h of toxin
treatment, which became more pronounced at 1.5 h and 2 h
(Fig. 1C). By 3 h of toxin treatment, an almost maximal reduction
in metabolic activity was observed. Remarkably, 10 mM celastrol
was able to completely protect cells that had been exposed to LeTx
for 1.5 h and stopped further loss in metabolic activity in cells
exposed to toxin for 2 h (Figs. 1C, D). These results indicate that
celastrol protects cells by inhibiting a process that occurs late in
intoxication.
Since celastrol has been reported to inhibit proteasome activity
in prostate cancer cell lines [33], we assessed whether celastrol
might inhibit the proteasome-dependent degradation of proteins in
RAW264.7 cells. To test this idea, we treated RAW264.7 cells
with lipopolysaccharide (LPS) and probed cell lysates for IkB-a,
which is degraded by the proteasome in cells that have been
stimulated by LPS. Western blotting indicated that LPS treatment
Figure 1. Celastrol blocks LeTx-mediated cytolysis of RAW264.7 cells subsequent to MAPKK1 cleavage. (A) RAW264.7 cells were treated with 3 mM
celastrol and/or LeTx (10
28 M PA and 5610
210 M LF) as indicated for 4 h. Cell viability was assessed using the MTS assay. The means of three
experiments6SEM are reported. (B) RAW264.7 cells were treated with LeTx and/or 10 mM celastrol as indicated for 1 h. Cell lysates were subjected to
Western blotting using antibodies that detect MAPKK1 or a-tubulin. A representative result of three independent experiments is shown. (C)
RAW264.7 cells were exposed to LeTx for indicated amounts of time and viability was assessed using the MTS assay. The means of three
experiments6SEM are reported. (D) Celastrol (10 mM) was added to RAW264.7 cells at the indicated times after cells were treated with LeTx (black
bars) at t = 0 h or were not treated with toxin (white bars). Cell viability was assessed 4 h after LeTx addition by the MTS assay. The means of three
experiments6SEM are reported.
doi:10.1371/journal.pone.0001421.g001
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the proteasome inhibitor, MG132 (Fig. 2A). Celastrol was also able
to inhibit the degradation of IkB-a at a concentration that
protected RAW264.7 cells from LeTx. As an additional test of
whether celastrol inhibited the degradation of ubiquitylated
proteins, we treated cells with either MG132 or celastrol and
examined cell lysates for ubiquitylated proteins by Western
blotting with an anti-ubiquitin antibody (Fig. 2B). We observed
that treatment of cells with either MG132 or celastrol led to the
accumulation of ubiquitylated proteins, suggesting that celastrol
inhibits a step in the proteasome pathway. Interestingly, celastrol
treatment resulted in the accumulation of more ubiquitylated
proteins than did MG132. Because MG132 is a potent inhibitor of
the proteasome, we speculated that the ability of celastrol to cause
a greater accumulation of ubiquitylated proteins than MG132
might be a result of an additional activity of celastrol that induces
the accumulation of misfolded proteins. Indeed, celastrol has been
reported to inhibit HSP90 [34]; inhibition of HSP90 would cause
an accumulation of misfolded proteins that would subsequently be
ubiquitylated. To test this hypothesis, we treated cells with either
celastrol or MG132 in the presence or absence of the HSP90
inhibitor geldanamycin (Fig. 2C). The combination of geldana-
mycin and celastrol resulted in a level of ubiquitylated proteins
similar to that in cells treated with celastrol alone. In contrast,
geldanamycin increased the level of ubiquitylated proteins in cells
treated with MG132. These results indicate that the higher level of
ubiquitylated proteins in celastrol-treated cells compared to
MG132-treated cells results from the ability of celastrol to induce
protein misfolding (through the inhibition of HSP90) in addition to
inhibiting proteasome-mediated degradation of proteins.
We next assessed whether a threshold of total cellular
ubiquitylated proteins was required to protect RAW264.7 cells
from LeTx. Cells were treated with LeTx in the presence of
various concentrations of either celastrol or MG132 and the cells
were assessed for viability. Celastrol protected cells at a
concentration of 3 mM, but not at 1 mM; MG132 protected cells
at 1 mM, but not at 0.3 mM (Fig. 2D). Because there are slightly
more ubiquitylated proteins in cells treated with 1 mM celastrol
than in cells treated with 1 mM MG132 (Fig. 2B), we conclude that
there is not a direct correlation between the bulk accumulation of
ubiquitylated proteins and the protection of cells from intoxica-
tion. It is possible that inhibiting the degradation of only one or a
few ubiquitylated proteins prevents LeTx-mediated cytolysis.
Ubistatins are compounds that block proteasome-mediated
protein degradation by binding ubiquitin chains, thereby inhib-
iting the interaction between ubiquitylated proteins and the
proteasome [35]. To determine if celastrol functions similarly, we
assessed whether celastrol blocked the ability of the ubiquitin
receptor S5a to bind ubiquitylated proteins. Glutathione-S-
transferase (GST) or a GST-S5a fusion protein was attached to
glutathione-sepharose beads and the beads were mixed with
RAW264.7 cellular lysates and then centrifuged to isolate
associated proteins. The associated proteins were electrophoresed
on denaturing polyacrylamide gels and then probed with anti-
ubiquitin antibody (Fig. 3). GST-S5a precipitated ubiquitylated
Figure 2. Celastrol inhibits the proteasome-dependent degradation
of proteins. (A) RAW264.7 cells were treated with 3 mM celastrol or
10 mM MG132 (or DMSO vehicle) for 30 min, followed by a 10 min
treatment with 1 mg/mL LPS. Cellular lysates were prepared and probed
for IkB-a or a-tubulin by Western blotting. A representative result of
three independent experiments is shown. (B) RAW264.7 cells were
treated with indicated concentrations of celastrol or MG132 for 1 h.
Cellular lysates were prepared and probed with anti-ubiquitin or anti-a-
tubulin. A representative result of three independent experiments is
shown. (C) RAW264.7 cells were treated with 10 mM celastrol, 10 mM
MG132 and/or 10 mM geldanamycin for 1 h. Cellular lysates were
prepared and probed with anti-ubiquitin or anti-a-tubulin. A represen-
tative result of three independent experiments is shown. (D) RAW264.7
cells were treated with various concentrations of celastrol or MG132 in
the presence (black bars) or absence (white bars) of LeTx for 4 h. Cell
viability was assessed using the MTS assay. The means of three
experiments6SEM are reported.
doi:10.1371/journal.pone.0001421.g002
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S5a from binding ubiquitylated proteins, suggesting that celastrol
does not interfere with the binding of ubiquitin chains to the
proteasome.
We next assessed whether celastrol inhibited the proteolytic
activity of the proteasome. The 26S proteasome is a large multi-
subunit complex consisting of a 20S barrel-shaped core complex
and two 19S regulatory complexes [36]. The regulatory complexes
ensure that only ubiquitylated proteins access the inside of the
barrel where the proteolytic sites reside. The proteasome exhibits
three distinct proteolytic activities, chymotrypsin-like, trypsin-like,
and caspase-like, which can be assayed individually using
fluorogenic substrates [37]. The chymotrypsin-like site is thought
to be the most important of the three, although the trypsin-like and
caspase-like activities must also be inhibited to reduce the
degradation of most proteins by 50% [37]. We mixed purified
26S proteosome with the fluorogenic substrate N-succinyl-Leu-
Leu-Val-Tyr-7-amido-4-methylcoumarin (Suc-LLVY-AMC) to
measure chymotrypsin-like activity; t-butoxycarbonyl-Leu-Arg-
Arg-7-amido-4-methylcoumarin (Boc-LRR-AMC) to measure
trypsin-like activity; or acetyl-L-norleucyl-L-prolyl-L-norleucyl-L-
aspartyl-methylcoumarylamide (Ac-nLPnLD-AMC) to measure
caspase-like activity. Whereas MG132 inhibited cleavage of the
three substrates, neither 3 mM nor 10 mM celastrol was able to
inhibit cleavage of the substrates by the 26S proteasome (Fig. 4A).
Celastrol showed some inhibitory activity against the chymotryptic
acivity of the 20S proteasome at 10 mM, but not at 3 mM (Fig. 4B),
a concentration that was sufficient to cause the accumulation of
ubiquitylated proteins in vivo (Fig. 2B). To test further whether
celastrol inhibited proteasome activity, we incubated RAW264.7
cell lysates with Suc-LLVY-AMC. MG132 reduced the rate of
cleavage of this substrate, but celastrol exhibited little inhibitory
activity (Fig. 4C).
Since it has been reported previously that inhibition of
proteasome activity prevents activation of the Nalp1b inflamma-
some [38,39], we sought to determine whether celastrol inhibits
processing of IL-18 by the Nalp1b inflammasome. RAW264.7
cells were incubated with LeTx in the absence or presence of
celastrol for 2 h and cellular lysates and supernatants were
Figure 4. Celastrol is not a potent inhibitor of the proteasome in
vitro. (A) The chymotrypsin-like (black bars), caspase-like (white bars),
and trypsin-like (grey bars) activities of purified 26S proteasome were
assessed in the presence or absence of celastrol or MG132. (B) The
chymotrypsin-like activity of purified 20S proteasome was assessed in
the presence or absence of celastrol or MG132. (C) The chymotrypsin-
like activity of the proteasome in RAW264.7 cell lysate was assessed in
the presence or absence of celastrol or MG132. Values represent the
means of three experiments6SEM.
doi:10.1371/journal.pone.0001421.g004
Figure 3. Celastrol does not inhibit the interaction between
ubiquitylated proteins and S5a. Cellular lysates were incubated with
either GST or GST-S5a coupled to glutathione-sepharose in the
presence or absence of celastrol, as indicated. Associated proteins
were precipitated, subjected to SDS-PAGE and probed for ubiquitin by
Western blotting. A representative result of three independent
experiments is shown.
doi:10.1371/journal.pone.0001421.g003
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18. The 18 kDa mature form of IL-18 was observed in lysates
derived from cells treated with LeTx and a reduced amount was
present in lysates derived from cells treated with both LeTx and
celastrol; no IL-18 was detected in the cell supernatants in these
conditions (Fig. 5). J774A.1 cells that were treated with LeTx had
a reduced amount of the 24 kDa form of IL-18 in cell lysates; the
processed form was observed in the supernatants. The stimulation
of IL-18 processing by LeTx was reduced in cells that were co-
treated with celastrol (Fig. 5). These results are consistent with
celastrol inhibiting an intoxication step upstream of Nalp1b
inflammasome activation.
In summary, we have demonstrated that celastrol inhibits LeTx-
induced cytolysis of RAW264.7 murine macrophage cells. The
concentrations required to protect cells (Fig. 2D) were similar to
the concentrations that led to the accumulation of ubiquitylated
proteins (Fig. 2B). Comparison of celastrol with MG132, however,
suggested that protection from cytolysis did not correlate with a
threshold level of total ubiquitylated proteins – this suggests that
the degradation of a relatively small subset of ubiquitylated
proteins may be required for cytolysis. The spectrum of
ubiquitylated proteins likely differs between celastrol-treated and
MG132-treated cells because celastrol inhibits HSP90, which
helps to fold a variety of proteins, in addition to inhibiting
proteasome-mediated degradation of proteins. Inhibition of
HSP90 by geldanamycin did not protect cells from LeTx (data
not shown).
Proteasome activity has previously been implicated in LeTx-
mediated cytolysis by structurally unrelated proteasome inhibitors
[28]. Recently, a report suggested that celastrol inhibits 20S
proteasome activity [33]. Using a fluorogenic substrate, we did
detect a slight decrease in 20S proteasome activity in vitro, but not
in 26S proteasome activity – although 20S proteasome does exist
in cells, it is thought that the 26S proteasome is responsible for the
degradation of ubiquitylated proteins [37]. Thus, we believe that
celastrol either inhibits the proteolytic activity of the 26S
proteasome only in intact cells, or it inhibits another step in the
ubiquitin-proteasome pathway. Inhibition of the ubiquitin-protea-
some pathway is a potential therapeutic strategy for the treatment
of cancer and neurodegenerative diseases [40], so it will be of
interest to characterize further how celastrol inhibits this pathway
and to determine whether it could be used to treat anthrax.
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